Javascript must be enabled to continue!
Tumour angiogenesis: vascular growth and survival
View through CrossRef
Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with tumour cell invasion and stromatogenesis, i.e. the formation of specific connective tissue stroma amenable to easy penetration by endothelial and tumour cells. However, as the tumour continues its growth, the edge becomes the inner tumour area, and a new invading tumour front is formed by the multiplying malignant cells which outflank the initial edge. This process, which repeats itself again and again, forms the “relay race” model of tumour vascular growth and regression. At the heart of the tumour unfavourable environmental conditions prevail – hypoxia, acidity, lack of nutrients, failure of waste removal, and apoptosis rather than proliferation. Blood vessels and tumour cells are greatly decreased, but do not vanish, as tumour cells are shifting to anaerobic glycolysis, and blood vessels are turning into anti‐apoptotic pathways – vascular survival ability (VSA). Thus, assessing vascular density (VD) by simply counting “hot spots” at the edge of a tumour, where conditions are most favourable, is futile; it may reflect tumour angiogenic activity (TAA), but is not representative of genuine tumour vasculature. By combining vessel counts at the invading tumour front with those of the inner tumour areas a complete picture of tumour VD can be achieved. The thus formed four patterns of vascularization, designated as “edvin” (edge vsinner tumour area), are: edvin 1: low TAA/low VSA; edvin 4: high TAA/high VSA; edvin 2: low TAA/high VSA; and edvin 3: high TAA/low VSA. It is expected that this scheme will prove useful in the field of chemoradiotherapy and anti‐angiogenic treatment.
Title: Tumour angiogenesis: vascular growth and survival
Description:
Angiogenesis starts at the edge of a malignant epithelial tumour concurrently with tumour cell invasion and stromatogenesis, i.
e.
the formation of specific connective tissue stroma amenable to easy penetration by endothelial and tumour cells.
However, as the tumour continues its growth, the edge becomes the inner tumour area, and a new invading tumour front is formed by the multiplying malignant cells which outflank the initial edge.
This process, which repeats itself again and again, forms the “relay race” model of tumour vascular growth and regression.
At the heart of the tumour unfavourable environmental conditions prevail – hypoxia, acidity, lack of nutrients, failure of waste removal, and apoptosis rather than proliferation.
Blood vessels and tumour cells are greatly decreased, but do not vanish, as tumour cells are shifting to anaerobic glycolysis, and blood vessels are turning into anti‐apoptotic pathways – vascular survival ability (VSA).
Thus, assessing vascular density (VD) by simply counting “hot spots” at the edge of a tumour, where conditions are most favourable, is futile; it may reflect tumour angiogenic activity (TAA), but is not representative of genuine tumour vasculature.
By combining vessel counts at the invading tumour front with those of the inner tumour areas a complete picture of tumour VD can be achieved.
The thus formed four patterns of vascularization, designated as “edvin” (edge vsinner tumour area), are: edvin 1: low TAA/low VSA; edvin 4: high TAA/high VSA; edvin 2: low TAA/high VSA; and edvin 3: high TAA/low VSA.
It is expected that this scheme will prove useful in the field of chemoradiotherapy and anti‐angiogenic treatment.
Related Results
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Initiation of Acute Graft-Versus-Host Disease By Angiogenesis
Abstract
Angiogenesis and inflammation are two closely related processes and inhibition of angiogenesis can ameliorate inflammatory diseases by reducing the recruitm...
TRIB1 regulates tumour growth via controlling tumour-associated macrophage phenotypes and is associated with breast cancer survival and treatment response
TRIB1 regulates tumour growth via controlling tumour-associated macrophage phenotypes and is associated with breast cancer survival and treatment response
SummaryMolecular mechanisms that regulate tumour-associated macrophage (TAM) phenotype and function are incompletely understood. Here, we show that the pseudokinase TRIB1 is highly...
Tumour Immunology
Tumour Immunology
Abstract
Tumour immunology is central to our understanding of the mechanisms of both tumour rejection and tumour progression. Vir...
Enhancing oncolytic virotherapy by exosome-mediated microRNA reprograming of the tumour microenvironment
Enhancing oncolytic virotherapy by exosome-mediated microRNA reprograming of the tumour microenvironment
Abstract
Background
There has been limited success of cancer immunotherapies in the treatment of ovarian cancer (OvCa) to date,...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract
Introduction
Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
JAML overexpression in tumour vascular endothelial cells promotes cancer proliferation via angiogenesis through VEGF signalling pathway activation
JAML overexpression in tumour vascular endothelial cells promotes cancer proliferation via angiogenesis through VEGF signalling pathway activation
Abstract
Angiogenesis is a crucial process in tumour growth and metastasis.Junctional adhesion molecule-like protein (JAML) plays a role in various tumours; however, its ro...
Tetrac as an anti-angiogenic agent in cancer
Tetrac as an anti-angiogenic agent in cancer
The thyroid hormones T3 and T4 have emerged as pro-angiogenic hormones with important implications for cancer management. Endogenous circulating hormone levels may help stimulate c...
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma
Abstract
Background
The size of pancreatic ductal adenocarcinoma (PDAC) at diagnosis is an indicator of outcome. Previous studie...

